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A mong patients with severe aortic stenosis (AS), the development of heart failure symptoms correlates with disease severity and left ventricular (LV) hypertrophy and has been attributed to LV diastolic and systolic dysfunction. 1 While diastolic dysfunction (DD) is the result of chronic pressure overload and unfavorable myocardial remodeling, owing to impairment of LV relaxation and changes in diastolic filling dynamics, 2 systolic dysfunction may develop because of an excess in afterload and changes in LV contractility related to inadequate hypertrophy of the myocardium. 3 Transcatheter aortic valve replacement (TAVR) is the treatment of choice for inoperable and patients at increased surgical risk, and has emerged as a less-invasive therapeutic option for intermediate risk patients with symptomatic, severe AS. So far, only selected echocardiographic diastolic and systolic parameters have been evaluated after TAVR and their prognostic value is still subject to controversy. [4] [5] [6] The myocardial performance index Tei is recognized as echocardiographic parameter to determine overall cardiac performance and express global systolic and diastolic ventricular function. 7 While the prognostic value of Tei has been studied in patients with congestive heart failure and dilated cardiomyopathy, 8, 9 the diagnostic and prognostic role of Tei in patients with severe AS undergoing TAVR remains to be elucidated.
METHODS

Patient Population and Procedures
Between August 2007 and December 2015, consecutive patients with symptomatic, severe AS undergoing TAVR were entered into the Bern TAVR Registry, which is part of the SwissTAVI Registry, and were considered eligible for this analysis. 10 Patients were excluded in case non-Confédération Européenne-marked device were used, and in the absence of adequate echocardiographic data to assess Tei index within 3 months before TAVR or 1 month after TAVR. Furthermore, patients with persistent atrial fibrillation and a history of permanent pacemaker implantation without showing sinus rhythm at the time point of echocardiographic assessments were excluded. TAVR was performed according to local expertise and standard techniques using a default transfemoral strategy, as described previously. 11 The registry was approved by the local ethics committee, was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent to participate during prospective follow-up. The present work adheres to the AHA Journals' implementation of the Transparency and Openness Promotion Guidelines. In accordance with this policy, the Bern TAVR publication committee decided not to make the data, methods used during the analyses, and materials used to conduct the research available to any other person. However, we would consider sharing our data for purposes of scientific collaboration on request.
Echocardiography and Data Collection
All subjects underwent transthoracic echocardiography within 3 months before TAVR and at hospital discharge after TAVR. Routine echocardiographic follow-up assessment was recommended to be performed at 30 days after TAVR. For the assessment of echocardiographic measures, we selected 3 of 15 consecutive heart beats and used the average of each parameter. Images were recorded with a workstation allowing for offline analysis (Syngo Dynamics Workplace, version 9.5, Siemens Medical Solutions, Inc, PA). Before (pre-Tei) and after TAVR (post-Tei), the LV Tei index was calculated using the following equation: Tei index=(ICT+IRT)/ET, where ICT denotes isovolumic contraction time, IRT isovolumic relaxation time, and ET refers to the ejection time ( Figure I in the Data Supplement). The mitral inflow velocity pattern and the LV outflow velocity pattern were recorded from the apical 4-chamber view, and the apical long-axis view using pulsed wave Doppler, respectively. The predefined cutoff for normal Tei was <0.45, as previously reported. 12 The echocardiographic evaluation was independently performed by board-certified cardiologists and experienced echocardiographers who were blinded to patient outcomes.
Clinical Follow-Up and End Point Assessment
Clinical follow-up was standardized and performed at 30 days (early) and 1-year (longer-term) follow-up after TAVR. All adverse events were systematically collected and independently adjudicated according to the updated definitions of the Valve Academic Research Consortium-2. The primary end point was all-cause mortality within 1 year after TAVR.
Statistical Analysis
Continuous data are reported as means with SD (±SD, with P from t tests), and categorical variables are reported as
WHAT IS KNOWN
• The left-ventricular myocardial performance index
Tei is an echocardiographic parameter that incorporates the information of systolic and diastolic time intervals.
• While the prognostic value of selected systolic and diastolic parameters is well established after transcatheter aortic valve replacement, the role of Tei has not been evaluated in this setting.
WHAT THE STUDY ADDS
• We found an independent association of Tei index with worse clinical outcomes at 30 days and up to 1-year follow-up after transcatheter aortic valve replacement.
• Pre-transcatheter aortic valve replacement Tei index emerged as independent predictor of all-cause mortality at 30 days follow-up, whereas post-transcatheter aortic valve replacement Tei index was strongly associated with all-cause death, cardiovascular death, and major adverse cardiovascular and cerebrovascular events between 30 days and 1 year.
number of patients (% of patients, with P from χ 2 tests, or in case of 2-by-2 associations Fisher exact tests), comparing pre-Tei index high versus normal, and again comparing postTei index high versus normal.
Events are reported as counts of first occurrence per (sub)-type of event within 30 days or 1 year of follow-up (% of from lifetable estimates), comparing high pre-Tei versus normal pre-Tei index using Cox's regressions (ie, censoring patients at death or lost to follow-up). Reported are crude hazard ratios (HR with 95% CI) with P from Wald χ 2 tests, or continuity correct risk ratios with P from Fisher exact tests in case of zero events. Reported are adjusted HR (HR adj ; 95% CI), with the pre-Tei high compared with pre-Tei normal. Adjusted analyses conducted in case >10 events were available overall. Post-Tei index was assessed up to 1-month follow-up, accordingly high post-Tei index event rates were compared with normal post-Tei index using events reported from 30 days to 1 year of follow-up (by setting a landmark at 30 days, which includes only patients still at risk for that particular event starting from 30 days onwards). Again, both crude and HR adj (95% CI) are reported.
Predictors of 30-day clinical outcomes were evaluated separately (univariable Cox's regressions). Similarly, predictors of clinical outcomes between 30 days to 1 year after TAVR were evaluated separately (univariable Cox's regressions). These potential predictors were retained in the multivariable model, if the univariable P value was <0.2. The final model shows all potential predictors with P<0.2 in the multivariable model. Stratified analyses of the following subgroups were performed: sex (women versus men), LV ejection fraction (EF; <40% versus ≥40%), and Society of thoracic surgeon score (>8 versus 4-8 versus <4); and additionally the P value for the interaction between these subgroups (eg, women versus men) and Tei index are reported (high versus normal-separate tables for pre-and post-Tei index). Exploratory analyses of combinations of pre-Tei and post-Tei index on clinical end points were also conducted (Tables I through IX in the Data Supplement). All analyses were performed with Stata version 14.2 (StataCorp, College Station, TX). Two-sided P<0.05 were considered statistically significant.
RESULTS
Study Population
Out of 1339 consecutive patients undergoing TAVR during the study period, the evaluation of pre-and post-Tei index was performed in 824 patients (61.5%; normal pre-Tei; n=639, high pre-Tei; n=185), and 722 (53.9%) patients (normal post-Tei; n=602, high post-Tei; n=120), respectively ( Figure II in the Data Supplement).
Baseline clinical characteristics of the study population are described in Table 1 Table 2 provides the information on procedural characteristics between patient groups, showing significant differences in access route, valve type selection, and aortic regurgitation post TAVR greater than or equal to moderate among pre-Tei patients, whereas length of hospital stay, access route, valve type selection, and valve in series were different comparing normal and high post-Tei patients. A total of 182 patients received permanent pacemaker during the early periprocedural period after TAVR. 
Procedural Characteristics
Clinical Outcomes According to Pre-and Post-Tei Index
Event rates with crude and HR adj for clinical end points are provided in Tables 3 and 4 Table I in the Data Supplement). Significant differences were found in terms of access route, type of valve selection, and length of hospital stay comparing HH patients with NN (Table II in Table V in the Data Supplement.
Predictors for Adverse Clinical Outcomes
Independent predictors for death from any cause are displayed in Table 5 
DISCUSSION
The salient findings of our study investigating the association of periprocedural Tei index and clinical outcomes after TAVR can be summarized as follows:
1. One-quarter of patients undergoing TAVR for severe AS were found to have impaired LV myocardial performance according to the Tei index. No. of events (% from lifetable estimate). Hazard ratios (HR; 95% CI) from Cox regressions for time-to-event data. In case of >10 event also reported: Adjusted (HRs; 95% CI) from Cox regressions adjusting for diabetes mellitus, peripheral vascular disease, paroxysmal atrial fibrillation, BMI ≤20, logistic EuroSCORE ≥40%, concomitant PCI. Fisher exact test and continuity correct Risk ratios reported in case of zero events in 1 group. MACCE indicates major adverse cardiovascular and cerebrovascular events (composite of all-cause death, stroke, and myocardial infarction). No. of events (% from lifetable estimate). Hazard ratios (HR; 95% CI) from Cox regressions for time-to-event data. In case of >10 event also reported: Adjusted HRs (95% CI) from Cox regressions adjusting for diabetes mellitus, peripheral vascular disease, paroxysmal atrial fibrillation, BMI ≤20, logistic EuroSCORE ≥40%, concomitant PCI. Fisher exact test and continuity correct Risk ratios reported in case of zero events in 1 group. MACCE indicates major adverse cardiovascular and cerebrovascular events (composite of all-cause death, stroke, and myocardial infarction); and PCI, percutaneous coronary intervention.
*Landmark at 30 days, that is, excludes patients no longer at risk for the specified event at day 30.
2. Pre-Tei index was associated with worse clinical outcomes after TAVR and emerged as independent predictor of all-cause mortality at 30 days. 3. Moreover, post-Tei index was strongly associated with all-cause death, cardiovascular death, and MACCE between 30 days and 1 year. The LV Tei index is an established echocardiographic parameter of advanced heart disease and a wellknown predictor of worse clinical outcomes among patients with different types of cardiomyopathy, including ischemic, dilated, or hypertrophic heart disease. 8, 9 Furthermore, LV Tei is effective in the early detection of subclinical ventricular dysfunction in patients with insulin resistance 13 and is used as early reference marker for hypertensive cardiomyopathy in children with essential hypertension.
14 However, it lacks precision and reproducibility in patients with atrial fibrillation, pacemaker rhythm, frequent ventricular ectopic stimuli, and disturbances of intraventricular or atrioventricular conduction. 15 Our analysis suggests that LV Tei index also provides important prognostic information for patients with symptomatic, severe AS undergoing TAVR. While an elevated Tei index at baseline was associated with a 3.5-to 2.5-fold increased risk of mortality after 30 days and 12 months after TAVR, an increased Tei index after TAVR was found to be linked to a 6-fold increased risk of mortality and MACCE up to 1-year after TAVR. The adverse effect of high Tei index was observed irrespective of sex, Society of thoracic surgeons risk, and LVEF (Figure 2 ), which are well-established predictors for clinical outcomes after TAVR. LV Tei index is considered a global myocardial performance index as it incorporates time intervals of systolic and diastolic ventricular function from Doppler echocardiographic images. It is well established, that systolic LV dysfunction is associated with increased operative mortality after surgical aortic valve replacement, 16 and considered one of the main reasons to circumvent surgery in the past. While, in the PARTNER I trial (Placement of Aortic Transcatheter Valves; cohort B+A), patients with classical low-flow, low-gradient severe AS had worse clinical outcomes after 2 years compared with normal flow patients, 17 no significant differences in outcomes were observed between surgical aortic valve replacement and TAVR patients. Both treatment options were able to restore LVEF to a similar extent and provided comparable levels of LVEF improvement in the absence of right ventricle pacing or new onset left bundle branch block during follow-up. In contrast to the PARTNER data, a meta-analysis encompassing >7600 patients from 16 studies was able to show that reduced LVEF was associated with increased mortality at 1-year follow-up. This adverse effect was consistently observed in patients with LVEF <50% (HR 1.52; 95% CI, 1.31-1.76) and LVEF <30% (HR 1.60; 95% CI, 1.19-2.16). 18 Furthermore, among patients with symptomatic, severe AS, chronic pressure overload, and unfavorable myocardial remodeling because of cardiac hypertrophy is linked to impairment of LV relaxation and changes in diastolic filling. 2 After conventional surgical aortic valve replacement, moderate-to-severe DD has been associated with relevant difficulties in perioperative weaning of cardiopulmonary bypass and was associated with worse clinical outcomes during longer-term follow-up up to 2 years after surgery. 19, 20 Studies on the prognostic role of DD among patients undergoing TAVR are limited in number and patient size. 4, 21 Most recently, data from a single center registry suggest that baseline DD was associated with mortality at 12 months (HR 1.163; 95% CI, 1.049-1.277; P=0.005) and the end point death/cardiovascular hospitalization (HR 1.174; 95% CI, 1.032-1.318; P=0.018) after TAVR. However, DD post-TAVR or changes in DD grade from baseline to follow-up did not emerge as predictor for worse clinical outcomes in 90 TAVR patients. 4 Conte et al 21 investigated the prognostic role of LV stiffness as expression of DD and was able to show that increased myocardial stiffness was associated with mortality at 12 months. Patients with a combination of high LV stiffness and moderate-to-severe paravalvular AR after TAVR were at particular risk for worse clinical outcomes, according to this study.
In our study, the LV Tei index was associated with worse clinical outcomes during the first year after TAVR, irrespective whether baseline or post-TAVR measures were used in multivariate analysis. By including systolic and diastolic time intervals to calculate Tei, this index might be considered a marker of global cardiac function and a reference parameter of advanced heart disease in patients with symptomatic, severe AS undergoing TAVR. As Tei predicts worse clinical outcomes after TAVR irrespective of LVEF, future studies will show whether risk assessment using the standard surgical risk score algorithms may benefit from replacing systolic EF with LV Tei index.
Study Limitations
The findings of our study have to be interpreted in light of several limitations. First, the study population was based on the experience of a single, tertiary care center and the results might not be extrapolated to other centers with differences in patient selection and procedural experience. Second, we assessed pre-and post-Tei index in all patients irrespective of concomitant valvular heart disease (significant aortic/mitral regurgitation), coronary artery disease, or after pacemaker implantation, which might have a differential effect on Tei. Third, patients with permanent atrial fibrillation or paced cardiac rhythm at the time point of echocardiographic assessment had to be excluded because of the inability to provide a precise and reliable calculation of Tei in the absence of an A-wave. Finally, we report results from a relatively modest number of patients and not all consecutive patients had sufficient echocardiographic imaging quality to evaluate Tei pre-and post-TAVR. However, the current TAVR patient population provides the largest echo dataset evaluating the effect of Tei in the present literature, is used from a prospective registry, which adheres to high standards of data quality with rigorous data collection, standardized follow-up, and independent event adjudication at regular time intervals.
Conclusions
The LV myocardial performance index Tei is associated with impaired clinical outcomes after TAVR. Future studies will need to confirm the role of Tei as parameter for risk stratification in a patient population undergoing TAVR.
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